Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel (NASDAQ:CAPR)

Capricor Therapeutics (CAPR) upgraded to Buy as FDA accepts HOPE-3 for Deramiocel in DMD cardiomyopathy; PDUFA Aug 22, 2026. Click here to read more.

You will be redirected in 10 seconds.

liveinternet liveinternet